Cognitive decline after electroconvulsive therapy, based on psychiatric disorders

Zandifar, Atefeh; Badrfam, Rahim; Assareh, Marzieh; Pahlevan, Hossein Ali; Naji, Borzooyeh

doi:10.1016/j.ajp.2019.07.045

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ECT is more effective in treating psychiatric disorders, including depression [ 23 , 24 ]. However, the mechanisms by which ECT induced the onset of psychiatric symptoms such as delirium in patients have not been fully elucidated to date [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Dexmedetomidine Regulates the miR-146a-5p/NF-κB Axis to Alleviate Electroconvulsive Therapy-Induced Cognitive Impairments

Zhou

Wang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is a nonpharmacological treatment for depressive episodes and other psychiatric disorders. It is used to control the condition by causing a transient loss of consciousness through electrical stimulation. Dexmedetomidine (DEX) is a novel and highly selective adrenergic agonist with sedative, sympathetic nerve activity inhibiting and stress-responsive effects. This study focused on the effect of DEX on cerebral protection after ECT treatment. 68 depression patients were enrolled and divided into control group and DEX group. The occurrence of delirium after ECT treatment in depression cases was recorded. In vivo, we constructed chronic mild and unpredictable stress (CUMS) rats to mimic depression model. Meanwhile, ECT treatment and DEX injection were administrated in CUMS rats. Learning and memory in rats were measured by Morris water maze test, open field test (OFT), and forced swimming test (FST). Finally, the expression of miR-146a-5p and NF-κB was determined by RT-qPCR and western blot assay. The incidence of delirium after ECT treatment was prominently reduced in DEX group in relation to control group. In vivo, DEX injection had no effect on ECT treatment efficacy against depression conditions. After ECT treatment, the cognitive impairment was ameliorated in CUMS rats accomplished with decreased miR-146a-5p and increased NF-κB level. Finally, compared with ECT treatment, DEX injection could protect against depression-like behaviors by increasing miR-146a-5p level and inactivated NF-κB pathway. Overall, ECT-induced cognitive impairment in depression rats could be ameliorated by DEX injection via miR-146a-5p/NF-κB axis.

show abstract

Section: Discussionmentioning

confidence: 99%

Dexmedetomidine Regulates the miR-146a-5p/NF-κB Axis to Alleviate Electroconvulsive Therapy-Induced Cognitive Impairments

Zhou

Wang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Zandifar i wsp. [39] byli jednymi z naukowców, którzy badali taką zależność. Wykazali oni wahania zaburzeń poznawczych między następczymi sesjami EW, gdzie mniejsze nasilenie deficytu występowało u pacjentów ze schizofrenią w porównaniu z pacjentami z depresją.…”

Section: Czy Choroba Podstawowa Ma Znaczenie?unclassified

“…Wykazali oni wahania zaburzeń poznawczych między następczymi sesjami EW, gdzie mniejsze nasilenie deficytu występowało u pacjentów ze schizofrenią w porównaniu z pacjentami z depresją. W testach MMSE (popularny Mini-Mental State Examination), zaobserwowali poprawę funkcji po trzecim zabiegu EW i pogorszenie po pierwszym i ostatnim [39]. Nieco inne fluktuacje w sprawności poznawczej wykazał Hebbrecht [40], wprowadzając 4 przedziały czasowe: czynność poznawcza przed zabiegiem, przed trzecią procedurą EW, po tygodniu, trzech miesiącach i po pół roku od procedury.…”

Section: Czy Choroba Podstawowa Ma Znaczenie?unclassified